REFERENCES
- Collan Y, Torkkeli T, Kosma VM, Personen E, Kosunen O, Jantunen E, Mariuzzi GM, Montironi R, Marinelli F, Collina G. Sampling in diagnostic morphometry; the influence of variation sources. Patho Res Pract 1987; 182: 401–406.
- Esrig D, Spruck CH, Chaiwun B, Nichols PW, Groshen S, Skinner DG, Jones PA, Cote RJ. Immunohistochemical detection of p53 alterations correlated with mutations in the p53 gene, tumor grade, stage and prognosis in the bladder cancer. J Urol 1993; 149 (Suppl): 327A.
- Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992; 358: 83–86.
- Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531–539.
- Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393–1398.
- Herr HW, Jakse G, Sheinfeld J. T1 bladder tumor. Semin Urol 1990; 8: 254–261.
- Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig R. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304–6311.
- Lane DP. p53, guardian of the genome. Nature 1992; 358: 15–16.
- Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453–456.
- Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993; 53: 365–370.
- Marx J. New tumor suppressor may rival p53. Science 1994; 264: 344–345.
- Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–1805.
- Pines J. p21 inhibits cyclin shock. Nature 1994; 369: 520–521.
- Popov Z, Colombel M, Mazerolles C, Ravery V, Patard JJ, Abbou C, Bellot J, Chopin D. Evaluation of proliferation and p53 overexpression in bladder cancer. J Urol 1994; 151: 443A.
- Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z, Sheinfeld J, Fair RF, Herr HW, Reuter VE. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53–59.
- Schmitz-Drager BJ, van Roeyen CRC, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bultel H, Makri D, Ebert T, Ackermann R. p53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol 1994; 12: 79–83.
- Sidransky D, von Eisenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706–709.
- Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. Allelic losses of chromosomes 9, 11 and 17 in human bladder cancer. Cancer Res 1990; 50: 44–47.
- Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574–578.
- Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993; 8: 3427–3431.
- Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CHW, Neal DE. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 1991; 63: 967–970.
- Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704.
- Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345–347.